Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioCryst Stock Rises After White House Calls For Quicker Pace On Swine Flu Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Two Phase III trials are planned for a flu antiviral this year, but the company could be asked to provide supplies for U.S. emergency stockpile before approval.

You may also be interested in...



Shionogi Files Early NDA For Flu Drug Peramivir, Aims For 3 Million User Annual Supply

Shionogi announced Nov. 4 the company filed a new drug application for influenza drug peramivir with Japan's Ministry of Health, Labor and Welfare in October. The early NDA submission came just three month after the Osaka-based company completed a Phase III study for the drug

H1N1 Vaccine Update: Big Sales To Come In Fourth Quarter, Mfrs. Say

The pandemic influenza situation is leaving the biopharmaceutical industry in a healthy state - with early reports of vaccine sales having notable impact on manufacturers' bottom lines, revitalization for waning antiviral products and accelerated pathways for novel products

H1N1 Vaccine Update: Big Sales To Come In Fourth Quarter, Mfrs. Say

The pandemic influenza situation is leaving the biopharmaceutical industry in a healthy state - with early reports of vaccine sales having notable impact on manufacturers' bottom lines, revitalization for waning antiviral products and accelerated pathways for novel products

Topics

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel